Učitavanje...
Barriers and facilitators to early access of bedaquiline and delamanid for MDR-TB: a mixed-methods study
SETTING: Phase II trials for bedaquiline (BDQ) and delamanid (DLM) were completed by 2011 and the drugs were approved by stringent regulatory authorities for the treatment of multidrug-resistant tuberculosis (MDR-TB) between 2012 and 2014. Manufacturers established ‘early access’ mechanisms to provi...
Spremljeno u:
| Izdano u: | Public Health Action |
|---|---|
| Glavni autori: | , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
International Union Against Tuberculosis and Lung Disease
2019
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6436488/ https://ncbi.nlm.nih.gov/pubmed/30963040 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5588/pha.18.0078 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|